Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Single FT1050 treated UCB unit · 1 trial · 5 indications
To determine the minimally effective TNC dose for a single FT1050-treated CB unit based on neutrophil engraftment/chimerism when used for hematopoietic reconstitution following a reduced-intensity conditioning regimen for hematologic malignancies.
| Arm | Type | Description |
|---|---|---|
| Single FT1050 treated UCB Unit | EXPERIMENTAL | Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood |
| Name | Type | Description |
|---|---|---|
| Single FT1050 treated UCB unit | BIOLOGICAL | Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood |
Inclusion Criteria: 1. Subjects with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate. Eligible diseases and stages include: * Non-Hodgkin's lymphoma or Hodgkin's lymphoma * Chronic lymphocytic leukemia (CLL) * Acute myelogenous leuke...
Single FT1050 treated UCB unit is an investigational therapy being studied for use in Non-Hodgkin's Lymphoma (NHL). It is a single umbilical cord blood unit that has been treated ex vivo with FT1050. The therapy is in Phase 1 clinical development for this indication.
Single FT1050 treated UCB unit is being developed by Fate Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol FATE. The company is conducting clinical research on this investigational therapy for Non-Hodgkin's Lymphoma.
Single FT1050 treated UCB unit is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The therapy is being studied for Non-Hodgkin's Lymphoma, with one completed Phase 1 trial.
Single FT1050 treated UCB unit has one completed clinical trial, registered as NCT01527838. This Phase 1 study, titled "Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit," enrolled 10 participants in the United States with conditions including Non-Hodgkin's Lymphoma.
Single FT1050 treated UCB unit refers to an umbilical cord blood unit that has been treated with FT1050. FT1050 is the investigational agent used to modulate the cord blood unit ex vivo. The therapy is being developed by Fate Therapeutics for Non-Hodgkin's Lymphoma.